Recent studies have identified that the expression of EZH2 is altered in SLE patients, and targeted therapy against EZH2 ameliorates the clinical performance of lupus mice (Rohraff et al., 2019; Schrezenmeier et al., 2019). This evidence concerns the gene EZH2 and systemic lupus erythematosus.